Y V Srinivas Joins Converge Biotech as General Manager – Marketing

Y V Srinivas has been appointed as the General Manager – Marketing at Converge Biotech Pvt. Ltd., marking a significant milestone in the company’s leadership team. A seasoned marketing leader, Srinivas brings with him a wealth of experience in driving strategic initiatives aimed at strengthening brand presence, enhancing customer engagement, and accelerating market share across competitive pharmaceutical landscapes.
Prior to joining Converge Biotech, Srinivas held several key roles across prominent pharmaceutical organizations. He served as Group Product Manager at NATCO Pharma, MSN Laboratories, and Unichem Laboratories Limited, where he played a pivotal role in developing and executing marketing strategies for a wide portfolio of therapeutic segments. His tenure as Marketing Manager at Celon Laboratories Limited further underscores his expertise in brand management and lifecycle planning.
Srinivas also held the position of Assistant General Manager – Business Development at Gland Pharma Limited, where he contributed to expanding market footprints through strategic partnerships and business collaborations. Earlier in his career, he built a strong foundation in sales and field operations through roles such as Scientific Sales Executive at Sanofi-Aventis, Serdia Pharmaceuticals (I) Ltd., and as a Medical Sales Representative at Ranbaxy. He also served as Senior Territory Manager at Eli Lilly, where he honed his skills in customer relationship management and market penetration.
With a career trajectory that showcases both depth and diversity in pharmaceutical marketing, Y V Srinivas is poised to bring strong leadership and innovation to Converge Biotech’s marketing function. His appointment is expected to further strengthen the company’s mission of delivering quality healthcare solutions and building sustainable market strategies. https://cxolanes.com/leadership-moves/others/y-v-srinivas-joins-converge-biotech-as-general-manager-marketing/
Comments
Post a Comment